DiaMedica Therapeutics Inc. (DMAC) Dividend History

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and kidney diseases. It leverages its proprietary DM200 monoclonal antibody platform to target complement-mediated diseases, aiming to address unmet medical needs in stroke, neurodegeneration, and kidney disorders.

301 Carlson Parkway, Minneapolis, MN, 55305
Phone: (763) 496-5454
Website:

Dividend History

DiaMedica Therapeutics Inc. currently does not pay dividends

Company News

  • DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke.

    Zacks Investment Research
    Featured Companies: ADMA ANVS FGEN
  • DiaMedica Therapeutics (DMAC) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

    Zacks Investment Research
  • Here is how Cardiol Therapeutics Inc. (CRDL) and DiaMedica Therapeutics, Inc. (DMAC) have performed compared to their sector so far this year.

    Zacks Investment Research
    Featured Companies: CRDL
  • Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.

    Zacks Investment Research
  • Upgrades For DiaMedica Therapeutics Inc (NASDAQ:DMAC), Oppenheimer upgraded the previous rating of Perform to Outperform. In the first quarter, DiaMedica Therapeutics showed an EPS of $0.20, compared to $0.13 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.05 and a 52-week-low of $1.12. DiaMedica Therapeutics closed at $3.64 at the end of the last trading period. For Kellogg Co (NYSE:K), Bernstein upgraded the previous rating of Underperform to Market Perform. For the first quarter, Kellogg had an EPS of $1.10, compared to year-ago quarter EPS of $1.10. At the moment, the stock has a 52-week-high of $77.16 and a 52-week-low of $63.74. Kellogg closed at $65.24 at the end of the last trading period. For Agree Realty Corp (NYSE:ADC), Mizuho upgraded the previous rating of Neutral to Buy. Agree Realty earned $0.98 in the first quarter, compared to $0.97 in the year-ago quarter. At the moment, the stock has a 52-week-high of $80.41 and a 52-week-low of $63.34. Agree Realty closed at $65.19 at the end of the last trading period. For Grab Holdings Inc (NASDAQ:GRAB), JP Morgan upgraded the previous rating of Underweight to Neutral. In the first quarter, Grab Hldgs showed an EPS of $0.06, compared to $0.11 from the year-ago quarter. At the moment, the stock has a 52-week-high of $4.03 and a 52-week-low of $2.19. Grab Hldgs closed at $3.39 at the end of the last trading period. For XP Inc (NASDAQ:XP), B of A Securities upgraded the previous rating of Neutral to Buy. For the first quarter, XP had an EPS of $0.28, compared to year-ago quarter EPS of $0.28. The current stock performance of XP shows a 52-week-high of $25.18 and a 52-week-low of $10.30. Moreover, at the end of the last trading period, the closing price was at $24.52. See all analyst ratings upgrades. Downgrades For Dow Inc (NYSE:DOW), B of A Securities downgraded the previous rating of Neutral to Underperform. For the first quarter, Dow had an EPS of $0.58, compared to year-ago quarter EPS of $2.34. At the moment, the stock has a 52-week-high of $60.88 and a 52-week-low of $42.92. Dow closed at $51.88 at the end of the last trading period. For The AES Corp (NYSE:AES), B of A Securities downgraded the previous rating of Buy to Neutral. In the first quarter, AES showed an EPS of $0.22, compared to $0.21 from the year-ago quarter. The current stock performance of AES shows a 52-week-high of $29.87 and a 52-week-low of $18.91. Moreover, at the end of the last trading period, the closing price was at $20.98. For Celanese Corp (NYSE:CE), B of A Securities downgraded the previous rating of Buy to Neutral. Celanese earned $2.01 in the first quarter, compared to $5.54 in the year-ago quarter. The stock has a 52-week-high of $128.35 and a 52-week-low of $86.73. At the end of the last trading period, Celanese closed at $108.52. For The Chemours Co (NYSE:CC), B of A Securities downgraded the previous rating of Buy to Neutral. Chemours earned $0.98 in the first quarter, compared to $1.46 in the year-ago quarter. The stock has a 52-week-high of $38.34 and a 52-week-low of $23.60. At the end of the last trading period, Chemours closed at $33.95. For Enphase Energy Inc (NASDAQ:ENPH), OTR Global downgraded the previous rating of Mixed to Negative. For the first quarter, Enphase Energy had an EPS of $1.37, compared to year-ago quarter EPS of $0.79. At the moment, the stock has a 52-week-high of $339.88 and a 52-week-low of $152.15. Enphase Energy closed at $167.99 at the end of the last trading period. According to BMO Capital, the prior rating for Xcel Energy Inc (NASDAQ:XEL) was changed from Outperform to Market Perform. Xcel Energy earned $0.76 in the first quarter, compared to $0.70 in the year-ago quarter. At the moment, the stock has a 52-week-high of $77.63 and a 52-week-low of $56.92. Xcel Energy closed at $62.81 at the end of the last trading period. According to Oppenheimer, the prior rating for Equinix Inc (NASDAQ:EQIX) was changed from Outperform to Perform. For the first quarter, Equinix had an EPS of $8.59, compared to year-ago quarter EPS of $7.16. The current stock performance of Equinix shows a 52-week-high of $792.02 and a 52-week-low of $495.11. Moreover, at the end of the last trading period, the closing price was at $768.00. According to Morgan Stanley, the prior rating for Tesla Inc (NASDAQ:TSLA) was changed from Overweight to Equal-Weight. In the first quarter, Tesla showed ...Full story available on Benzinga.com

    Benzinga
Dividend data last updated 06/07/2025 02:51:50 UTC